Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Factors predicting durable remission after IFN therapy discontinuation in MPN patients

Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital, University of Paris, Paris, France, discusses a study aiming to evaluate the possibility of interferon-alpha (IFN) therapy discontinuation in patients with myeloproliferative neoplasms (MPN) who reach complete hematological remission (CHR). MPN patients who had discontinued IFN therapy were included in the study and predictive factors of remaining in CHR were identified. Low JAK2 V617F mutant allele burden and longer IFN treatment period were both independent predictive factors of remaining in CHR without treatment. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Advisory boards for Novartis, BMS, Abbvie, Geron